The best occipital nerve stimulation devices address chronic migraine through a treatment approach that emerged from clinical research and now reaches consumer accessibility. The occipital nerves at the base of the skull serve as targets for both surgical implants in severe chronic cases and non-invasive at-home stimulation for less severe but still disabling migraine patterns. Understanding which approach fits your specific situation requires honest evaluation of severity, treatment history, and realistic outcomes from each option.
Most chronic migraine sufferers discover occipital nerve stimulation after exhausting standard preventive medications. The propranolol that didn’t work. The topiramate has intolerable side effects. The Botox injections helped marginally, but cost too much without insurance coverage. Each medication failure or limitation pushes patients toward considering procedural and device-based alternatives, and occipital nerve stimulation represents one of the most-researched options in this category.
Quality occipital nerve stimulation approaches solve specific problems based on severity. Surgical implants address severe chronic migraine that has failed multiple medication classes — the most invasive but potentially most effective option. Transcutaneous external stimulators provide non-invasive at-home treatment for moderate chronic migraine. Combined approaches integrate occipital stimulation with related neuromodulation for comprehensive migraine management.
This article provides educational information about occipital nerve stimulation but doesn’t replace professional medical evaluation. Persistent or severe migraines warrant consultation with headache specialists, particularly those certified by the United Council for Neurologic Subspecialties. The strategies discussed here support but don’t replace professional medical guidance.
If you’re managing migraines comprehensively, our Cefaly review, best red light therapy devices for migraine, and best migraine relief products guides cover complementary approaches.
Understanding Occipital Nerve Stimulation
The greater and lesser occipital nerves play key roles in migraine pain
The greater occipital nerve and lesser occipital nerve emerge from the upper cervical spine and supply sensation to the back of the head, scalp, and parts of the upper neck. Beyond simple sensory function, these nerves connect to the trigeminal nerve system through the trigeminocervical complex — a neural junction implicated in many migraine mechanisms.
The connection matters because migraine pain often originates from or significantly involves the trigeminocervical complex. Beyond the temple and forehead pain that defines classical migraine presentation, many migraine sufferers experience the pain pattern starting at the base of the skull and radiating forward. The occipital nerves serve as both pain conductors and potential treatment targets for this radiating pattern.
Stimulation of the occipital nerves modulates the pain signaling that contributes to migraine episodes. Research published in journals including Cephalalgia and Headache has documented that controlled electrical stimulation of these nerves reduces migraine frequency, intensity, and duration in many chronic migraine patients. The mechanism involves changing how the nervous system processes pain signals rather than directly addressing migraine causes.
Surgical versus transcutaneous approaches differ significantly
Two fundamentally different approaches exist for occipital nerve stimulation. The choice between them depends on migraine severity, treatment history, and willingness to undergo invasive procedures.
Surgical implant systems involve implanted electrodes placed near the occipital nerves, connected to a battery pack typically implanted in the upper back or chest. The system delivers continuous or programmed electrical stimulation that the patient can adjust through external controllers. The approach addresses the most severe chronic migraine cases that have failed multiple medication classes.
Transcutaneous (external) stimulators apply electrical currents through the skin without implants. Beyond non-invasive accessibility, the external approach allows patients to try occipital nerve stimulation without surgical commitment. The trade-off is reduced precision compared to implanted electrodes that target nerves directly.
The two approaches don’t compete directly — they target different patient populations. Severe chronic migraine sufferers exploring last-resort options consider implants. Moderate chronic migraine sufferers wanting non-invasive treatment options consider transcutaneous devices.
Clinical evidence varies significantly between approaches
Research evidence for occipital nerve stimulation differs dramatically based on approach type and migraine severity. Match expectations to the actual evidence rather than marketing claims that may overgeneralize across approaches.
Implanted occipital nerve stimulation for chronic migraine has documented evidence from randomized controlled trials. Studies including the ONSTIM and PRISM trials have shown a 30-50% reduction in headache days in selected patients. However, the evidence remains controversial, with some major trials showing modest or non-significant primary endpoint differences from sham stimulation.
Transcutaneous occipital nerve stimulation has weaker evidence base than implanted alternatives. The few published studies show modest benefits in some patients, but the evidence base is significantly smaller than that of implanted devices. Patients considering transcutaneous options should set realistic expectations of modest potential benefit rather than dramatic improvement.
Combined neuromodulation approaches integrating occipital with other nerve targets show promising preliminary results. The Cefaly device, which we cover separately, targets supraorbital nerves rather than occipital nerves but represents a related approach with stronger evidence base for migraine prevention.
What to Look for in Occipital Nerve Stimulation Options
FDA approval and clinical evidence levels
FDA approval status varies significantly across occipital nerve stimulation options. Match the approval level to your safety and evidence requirements.
FDA-approved implanted systems exist primarily through approvals for related conditions (chronic pain, peripheral nerve stimulation). Direct FDA approval for migraine specifically is rare, with most occipital implants used off-label for chronic migraine, despite the off-label nature being well-established in headache medicine.
FDA-cleared transcutaneous devices include some products cleared for general pain or wellness applications. The clearance status indicates safety review, but doesn’t necessarily indicate efficacy for migraine specifically. Patient response varies significantly.
Devices without any FDA clearance or approval represent the highest risk. Beyond efficacy uncertainty, the absence of regulatory review means safety hasn’t been verified through standard processes. Avoid devices marketed for migraine treatment without clear FDA clearance documentation.
Headache specialist consultation matters more than device selection
The most important decision in considering occipital nerve stimulation isn’t device selection — it’s whether occipital nerve stimulation makes sense for your specific migraine pattern. This decision requires consultation with headache specialists certified through the United Council for Neurologic Subspecialties.
Headache specialists evaluate whether the occipital pain pattern responds to nerve blocks (a strong indicator that stimulation may help), whether previous medication trials have been adequate, whether the migraine pattern fits chronic migraine diagnostic criteria, and whether other treatment options remain unexplored. The evaluation typically involves multiple appointments and requires substantial documentation.
Without specialist evaluation, patients risk pursuing occipital nerve stimulation when other interventions would help more effectively. Beyond wasted resources, the device approach may delay appropriate treatment for migraine patterns that respond better to other approaches.
Insurance coverage varies dramatically
Insurance coverage for occipital nerve stimulation depends heavily on diagnosis specifics, prior treatment documentation, and individual insurance policies. Match expectations to actual coverage rather than assuming coverage will follow standard patterns.
Implanted systems for chronic migraine typically require extensive prior authorization documentation, including failed medication trials, headache specialist evaluation, and demonstration of chronic migraine criteria (15+ headache days monthly with 8+ migraine days). Even with documentation, denial rates remain high, with many patients undergoing multiple appeals before approval.
Transcutaneous devices typically aren’t covered by insurance because they’re considered consumer wellness products rather than medical devices. The out-of-pocket cost ranges from $300-1500 depending on device complexity and features.
Out-of-pocket implant costs (for patients without insurance coverage) range from $30,000-50,000 for the implant procedure alone, before considering battery replacements every 5-10 years and ongoing programming adjustments. The substantial cost limits access for many patients regardless of medical appropriateness.
The 5 Best Occipital Nerve Stimulation Options in 2026
#1 — Medtronic Octrode System (Implanted)
Best Implanted System for Chronic Migraine | Score: 9.4/10 | Price: ~$30,000-50,000 procedure (with possible insurance coverage)
Check Price on AmazonThe Medtronic Octrode system represents the most-implanted occipital nerve stimulation option for chronic migraine. Beyond the established track record, Medtronic’s neurostimulation portfolio provides the longest history of supporting healthcare providers managing implanted nerve stimulation patients across years of follow-up care.
Why Medtronic Sets the Standard for Implanted Systems
The Octrode lead design uses 8-electrode configurations that allow precision targeting of the greater and lesser occipital nerves. Beyond initial placement, the multiple electrode options provide programming flexibility when nerve positioning shifts slightly over time, common in 3-5 year follow-up periods.
The implantable pulse generator (IPG) battery typically lasts 5-10 years, depending on stimulation intensity and frequency. Beyond standard battery technology, Medtronic offers rechargeable IPG options that extend functional life to 10-15+ years through periodic external charging rather than surgical battery replacement.
External patient programmers allow stimulation adjustment without office visits. Beyond initial programming, patients can modify intensity within physician-set parameters to match daily needs and migraine severity changes.
The Medtronic global presence ensures ongoing technical support and replacement parts availability. Beyond initial implant, the long-term support matters meaningfully because implants require periodic adjustments and eventual battery replacements.
Clinical research support through Medtronic-funded studies has produced the largest evidence base for occipital nerve stimulation in migraine. Beyond marketing claims, the data support the device’s positioning as a serious treatment option for selected patients.
The trade-offs match the implanted approach. The procedure requires surgical implantation under general or local anesthesia. Lead migration affects 10-15% of patients, sometimes requiring revision surgery. Infection risk exists at implant sites, though modern infection prevention reduces rates significantly. Battery replacement procedures every 5-10 years require additional surgical interventions.
The cost-benefit math depends heavily on insurance coverage. With insurance approval, out-of-pocket costs for chronic migraine patients typically range from $5,000-15,000 across the implant procedure. Without insurance, costs reach $30,000-50,000 for the implant alone.
PROS:
- Most-implanted system with an established track record
- 8-electrode precision targeting
- 5-15-year battery options, including rechargeable
- External patient programming
- Largest clinical evidence base
- Global Medtronic support
CONS:
- Surgical procedure required
- 10-15% lead migration rate
- Battery replacement surgeries
- Major insurance approval challenges
- $30,000-50,000 cost without insurance
Best for: Severely affected chronic migraine sufferers — particularly those who have failed 3+ medication classes and have a specialist evaluation supporting implant candidacy.
#2 — Boston Scientific Precision Spectra (Implanted)
Best Premium Implanted System | Score: 9.2/10 | Price: ~$35,000-55,000 procedure
Check Price on AmazonThe Boston Scientific Precision Spectra represents the premium implanted occipital nerve stimulation option with advanced technology features beyond Medtronic alternatives. Beyond construction, the multiple independent current control technologies provide programming sophistication that simpler systems cannot match.
Premium Implanted Technology
Multiple Independent Current Control technology delivers precise stimulation patterns to specific nerve regions. Beyond standard programming, the technology allows programming customization that adapts to individual nerve anatomy variations between patients.
The 32-contact implantable pulse generator provides more programming flexibility than 16-contact alternatives. Beyond initial setup, the additional contacts allow long-term programming adjustments as nerve positioning or pain patterns change.
Wireless programming through proprietary tablet-based systems eliminates older external controllers. Beyond convenience, the tablet interface allows more complex programming patterns than simpler controllers permit.
The trade-offs match the premium positioning. Higher upfront procedural costs than Medtronic alternatives. A smaller global presence may affect long-term support availability. Newer technology has a shorter long-term track record despite advanced features.
For patients with complex chronic migraine patterns requiring sophisticated programming, the Precision Spectra provides advanced capability. For typical chronic migraine cases without unusual programming needs, Medtronic alternatives offer comparable function at lower cost.
PROS:
- Multiple Independent Current Control
- 32-contact programming flexibility
- Tablet-based wireless programming
- Premium technology features
- Boston Scientific support
CONS:
- Higher cost than Medtronic
- Smaller user base
- Newer technology track record
- Less established support network
Best for: Complex chronic migraine cases requiring sophisticated programming — particularly those with mixed pain patterns or unusual nerve anatomy.
#3 — Cefaly DUAL (Transcutaneous Trigeminal — Closely Related)
Best Non-Invasive Alternative to Occipital Stimulation | Score: 9.3/10 | Price: ~$400
Check Price on AmazonThe Cefaly DUAL targets supraorbital nerves rather than occipital nerves specifically, but represents the most clinically validated non-invasive neuromodulation alternative for migraine sufferers considering occipital stimulation. Beyond direct comparison, the device serves as the typical first-line non-invasive trial before considering more invasive occipital approaches.
Clinically Validated Non-Invasive Alternative
FDA clearance for both acute migraine treatment and migraine prevention provides regulatory confidence that pure consumer wellness devices lack. Beyond clearance, the specific clearance for migraine indications matters more than general pain or wellness clearance.
Clinical trials published in Neurology and Cephalalgia journals have documented a 30-40% reduction in monthly migraine days with consistent prevention protocol use. Beyond marketing claims, the published data support the device’s effectiveness for properly selected patients.
The supraorbital nerve target connects to migraine pain pathways through similar mechanisms as occipital stimulation. Beyond direct nerve differences, the trigeminocervical complex involvement means many migraine sufferers respond similarly to either trigeminal or occipital approaches.
Over-the-counter availability without prescription requirements removes the access barriers that prescription-only alternatives create. Beyond convenience, the accessibility allows trial periods that establish whether neuromodulation helps before considering more invasive options.
The 60-day return policy accommodates response evaluation periods. Beyond standard returns, the policy specifically accommodates the 4-8 week trial periods that neuromodulation requires for fair evaluation.
For migraine sufferers considering occipital nerve stimulation, the Cefaly DUAL provides the most appropriate first trial. If Cefaly produces a meaningful response, the patient may benefit from related neuromodulation approaches, including occipital stimulation. If Cefaly fails to help, occipital stimulation likely won’t help either, saving substantial expense and procedural risk.
PROS:
- FDA-cleared for migraine specifically
- Strongest non-invasive evidence-based
- 60-day return policy
- Over-the-counter availability
- $400 vs $30,000+ implant cost
- Indicates likely occipital stimulation response
CONS:
- Targets trigeminal, not the occipital nerves directly
- Different nerve target than implants
- Adhesive electrodes need replacement
- Modest 30-40% improvement rates
Best for: Migraine sufferers considering neuromodulation approaches — particularly those wanting evidence-based non-invasive trial before considering invasive options.
#4 — Theragun Mini (Off-Label Massage Stimulation)
Best At-Home Mechanical Approach | Score: 8.8/10 | Price: ~$200
Check Price on AmazonThe Theragun Mini provides percussion massage that some chronic migraine patients use to address occipital muscle tension contributing to migraine patterns. Beyond standard massage applications, focused use at the base of the skull addresses the cervicogenic component that affects many migraine sufferers.
Mechanical Stimulation for the Occipital Region
Theragun’s percussion massage delivers focused mechanical stimulation that some patients find helpful for occipital region tension. Beyond standard massage, the percussion frequency provides faster muscle release than manual massage techniques.
The compact size allows precise application at specific occipital region trigger points. Beyond convenience, the targeted application matches the nerve location anatomy that informs occipital stimulation generally.
Multiple speed settings accommodate different sensitivity levels. Beyond comfort, the variable intensity allows progression from gentle introduction to more intense treatment as patients develop tolerance.
Important caveats: this is NOT electrical nerve stimulation. The Theragun provides mechanical massage that may help with muscle tension contributing to migraine, but doesn’t directly stimulate the occipital nerves themselves. Many chronic migraine patients confuse these mechanisms when considering options.
For patients with cervicogenic migraine components, the mechanical approach may provide benefits without the complexity of electrical nerve stimulation. For patients without significant muscle tension components, mechanical approaches likely won’t help meaningfully.
The trade-off is the limited evidence base, specifically for migraine. While massage and trigger point therapy have documented benefits for cervicogenic headache, the evidence for percussion massage specifically remains limited compared to standard manual therapy approaches.
PROS:
- Non-electrical mechanical alternative
- Compact for precise targeting
- Multiple speed settings
- Reasonable mid-range pricing
- Accessible without a prescription
- Adjustable intensity
CONS:
- Not actual nerve stimulation
- Limited migraine-specific evidence
- Works only for muscle-tension components
- Not a substitute for medical treatment
Best for: Patients with cervicogenic migraine components — particularly those experiencing occipital muscle tension as part of migraine patterns.
#5 — Generic TENS Units (Off-Label Use)
Most Accessible Transcutaneous Approach | Score: 8.2/10 | Price: ~$30-100
Check Price on AmazonGeneric TENS (Transcutaneous Electrical Nerve Stimulation) units provide the most accessible electrical stimulation option for occipital region application. While not specifically designed or FDA-cleared for migraine treatment, TENS units allow patients to experiment with electrical stimulation at the occipital region through proper electrode placement.
Accessible Electrical Stimulation Trial
TENS units provide controllable electrical stimulation at adjustable intensities. Beyond pain management applications, careful electrode placement at the occipital region creates stimulation patterns similar to dedicated occipital nerve stimulators.
Multiple intensity settings allow gradual progression from gentle introduction to therapeutic levels. Beyond comfort, the adjustability lets patients find the minimum effective stimulation intensity for their specific response patterns.
Battery operation provides portability that prescription devices may lack. Beyond convenience, the portability allows treatment during early prodrome symptoms for which prescription devices may not be available.
More Information
Cost accessibility at $30-100 makes an electrical stimulation trial possible without major investment. Beyond initial cost, the accessibility allows experimentation with different stimulation patterns and electrode placements.
Important caveats: TENS units aren’t FDA-cleared specifically for migraine treatment. The off-label use carries no regulatory safety review for the specific application. Patients should consult healthcare providers before applying electrical stimulation to the head and neck region, particularly with implanted medical devices, pregnancy, or neurological conditions.
The trade-offs match the off-label nature significantly. No clinical evidence specifically supports generic TENS for migraine treatment. Electrode placement at the occipital region requires careful learning to avoid stimulation of unintended structures. Self-administered electrical stimulation always carries some safety considerations that professional medical supervision addresses.
For patients wanting to experiment with electrical stimulation concepts before considering FDA-cleared alternatives, TENS units provide a minimum-investment trial capability. For serious migraine treatment, FDA-cleared alternatives like Cefaly provide a better evidence base and safety profile despite higher cost.
PROS:
- Lowest electrical stimulation pricing
- Battery portability
- Adjustable intensity ranges
- Widely accessible
- Allows concept experimentation
- Multi-purpose pain device
CONS:
- Not FDA-cleared for migraine
- No specific migraine evidence
- Off-label use safety considerations
- Electrode placement learning required
- Should not replace medical care
Best for: Migraine sufferers wanting to experiment with electrical stimulation concepts before considering FDA-cleared alternatives — only with healthcare provider awareness.
Quick Comparison: Best Occipital Nerve Stimulation Options in 2026
| Option | Type | Cost | FDA Status | Evidence Level | Score |
|---|---|---|---|---|---|
| Medtronic Octrode | Implanted | $30K-50K | Off-label use | Strong | 9.4 |
| Cefaly DUAL | External (trigeminal) | $400 | Cleared for migraine | Strong | 9.3 |
| Boston Scientific Precision Spectra | Implanted | $35K-55K | Off-label use | Moderate | 9.2 |
| Theragun Mini | Mechanical | $200 | General massage | Limited | 8.8 |
| Generic TENS Units | External | $30-100 | Off-label use | None for migraine | 8.2 |
How to Choose the Right Approach
The decision depends on migraine severity, treatment history, and willingness to consider invasive options.
Match the approach to migraine severity
Severe chronic migraine (15+ days monthly, 8+ migraine days, multiple medication failures, significant disability) may warrant consideration of implanted systems. Beyond severity, the medication failure history matters meaningfully — patients with treatment-naive chronic migraine should exhaust standard prevention before considering implants.
Moderate chronic migraine (8-14 monthly migraine days, some medication failures, partial disability) typically benefits from non-invasive alternatives like Cefaly DUAL. Beyond severity matching, the non-invasive trial helps establish whether neuromodulation approaches help individual patients.
Episodic migraine (less than 8 monthly migraine days) generally doesn’t justify occipital nerve stimulation regardless of approach. Beyond severity considerations, the procedural and cost burden exceeds the typical benefit ratio for episodic migraine patterns.
Match approach to treatment history
Patients with adequate medication trial history (3+ preventive classes including beta blockers, anticonvulsants, antidepressants) may consider implants if specialist evaluation supports candidacy. Beyond medication history, the specialist consultation matters — primary care providers typically lack the specialized evaluation expertise.
Patients with limited medication trial history should generally complete standard prevention attempts before considering occipital stimulation. Beyond clinical guidelines, the medication approach typically provides better outcomes for less complex chronic migraine cases.
Match the approach to invasiveness tolerance
Patients comfortable with surgical procedures may consider implanted systems if specialist evaluation supports candidacy. Beyond procedural comfort, the implant approach requires acceptance of revision risks, infection possibilities, and battery replacement procedures.
Patients preferring non-invasive options should focus on Cefaly DUAL or related transcutaneous alternatives. Beyond preference matching, the non-invasive approaches allow trial periods without procedural commitments.
For comprehensive migraine management, our Cefaly review, best red light therapy devices for migraine, and top migraine triggers guide cover complementary approaches.
Our Verdict
For migraine sufferers considering occipital nerve stimulation, the recommended starting point is the Cefaly DUAL at approximately $400. While the Cefaly targets trigeminal rather than occipital nerves specifically, the device serves as the appropriate first trial because it shares neuromodulation mechanisms with occipital approaches at significantly lower cost and risk. Patients responding to Cefaly may benefit from related neuromodulation approaches; patients failing to respond likely won’t benefit from occipital stimulation either.
For severe chronic migraine sufferers with adequate medication trial history and specialist support, the Medtronic Octrode System represents the most established implanted option. The estimated $30,000-50,000 procedural cost (often partially covered by insurance after extensive prior authorization) reflects the most-implanted track record and largest clinical evidence base for chronic migraine treatment.
More Information
For complex chronic migraine cases requiring sophisticated programming, the Boston Scientific Precision Spectra provides advanced technology features at premium pricing. The Multiple Independent Current Control and 32-contact programming flexibility serve cases that simpler implants cannot adequately address.
For patients with cervicogenic components, the Theragun Mini at $200 provides mechanical alternative addressing muscle tension that contributes to some migraine patterns. The mechanical approach differs fundamentally from electrical nerve stimulation but may help patients with significant tension components.
For patients wanting to experiment with electrical stimulation concepts before considering FDA-cleared alternatives, generic TENS units at $30-100 provide accessible trial capability. The off-label nature requires healthcare provider awareness and careful self-administration, but the minimum investment allows concept exploration.
The bigger principle is that occipital nerve stimulation represents one of several treatment options rather than a universal solution. The decision matrix prioritizes specialist evaluation over device selection, medication trial completion before considering implants, and non-invasive alternatives before considering invasive options. Patients pursuing occipital nerve stimulation through systematic evaluation typically have better outcomes than those pursuing it as a quick solution to chronic migraine.
For comprehensive migraine management, our Cefaly review, best red light therapy devices for migraine, best magnesium supplements for migraine prevention, and how to prevent menstrual migraines guides cover complementary approaches.
This article provides educational information about occipital nerve stimulation, but doesn’t replace professional medical evaluation. Severe or persistent migraines warrant consultation with headache specialists certified by the United Council for Neurologic Subspecialties for personalized treatment planning. New or significantly changing migraine patterns warrant prompt medical evaluation regardless of suspected causes.
Frequently Asked Questions
What is occipital nerve stimulation for migraine?
Occipital nerve stimulation involves controlled electrical stimulation of the greater and lesser occipital nerves at the base of the skull to reduce migraine frequency and intensity. The approach exists in two primary forms: surgical implants that place electrodes near the occipital nerves with implanted battery packs, and transcutaneous external stimulators that apply currents through the skin without implants. Research has documented benefits in selected patients, particularly those with chronic migraine who have failed multiple medication classes. The mechanism involves modulating pain signaling rather than directly addressing migraine causes.
Does occipital nerve stimulation actually work for migraine?
Evidence varies significantly based on approach and patient selection. Implanted occipital nerve stimulation has documented benefits in selected chronic migraine patients, with studies showing 30-50% reduction in headache days in randomized controlled trials. However, results are more modest than initial enthusiasm suggested, with some major trials showing limited differences from sham stimulation. Patient selection matters enormously — patients with documented chronic migraine, medication failure history, and specialist evaluation supporting candidacy show better outcomes than less rigorously selected patients. Set realistic expectations of meaningful but partial improvement rather than complete elimination of migraines.
How much does occipital nerve stimulation cost?
Costs vary dramatically by approach. Implanted systems cost $30,000-50,000 for the procedure and device, though insurance often covers the majority of costs after extensive prior authorization for qualifying patients. Battery replacements every 5-10 years require additional surgical procedures costing $10,000-20,000 each. Transcutaneous alternatives like Cefaly DUAL cost approximately $400 with ongoing electrode supply costs. Generic TENS units used off-label cost $30-100 for the device. Match cost expectations to your specific situation and insurance coverage rather than assuming standard cost patterns apply universally.
Is occipital nerve stimulation safe?
Both implanted and transcutaneous approaches have safety profiles, but the risk levels differ significantly. Implanted systems carry surgical risks including infection (1-5%), lead migration (10-15%), and rare serious complications including neurological injury. Battery replacement procedures every 5-10 years compound cumulative risk. Transcutaneous alternatives have minimal safety risks beyond skin irritation at electrode sites. Off-label TENS use requires healthcare provider awareness and proper electrode placement to avoid unintended structures. For all approaches, consultation with headache specialists ensures appropriate patient selection and safety considerations specific to individual medical histories.
What’s the difference between occipital nerve stimulation and Cefaly?
The Cefaly device targets supraorbital nerves (above the eyebrows) rather than occipital nerves (base of the skull). Both target nerves connected to the trigeminocervical complex are implicated in migraine, but the specific anatomy differs. Cefaly has FDA clearance specifically for migraine prevention and acute treatment with substantial clinical evidence. Occipital nerve stimulation lacks specific migraine FDA approval, though it’s used off-label based on supporting evidence. For patients considering neuromodulation approaches, Cefaly typically represents the appropriate first trial because of regulatory approval, accessibility, lower cost, and substantial clinical evidence — patients responding to Cefaly may benefit from related approaches, including occipital stimulation, while non-responders likely won’t benefit from occipital approaches either.
